Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Sep
17
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo